Clinical Trial Results:
Anti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and Placebo - Randomised, double-blind, placebo-controlled cohort trial
Summary
|
|
EudraCT number |
2014-003581-25 |
Trial protocol |
DE |
Global end of trial date |
14 Jun 2019
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
11 Nov 2021
|
First version publication date |
11 Nov 2021
|
Other versions |
|
Summary report(s) |
Adverse Events information_APAIII Primary endpoint statitical analysis |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
APA-III
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
University Hospital Tübingen
|
||
Sponsor organisation address |
Geissweg 3, Tübingen, Germany, 72076
|
||
Public contact |
Dr.med. Andreas Hector, University Children's Hospital, CPCS, +49 70712981341, andreas.hector@med.uni-tuebingen.de
|
||
Scientific contact |
Dr.med. Andreas Hector, University Children's Hospital, CPCS, +49 70712981341, andreas.hector@med.uni-tuebingen.de
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
12 Jun 2019
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
29 May 2019
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
14 Jun 2019
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
Difference in absolute FEV1 % predicted between verum and placebo at week 8 compared to baseline
|
||
Protection of trial subjects |
Patient's safety and well-being was taken in consideration during the whole procedure of the trial
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
20 Aug 2015
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Germany: 79
|
||
Worldwide total number of subjects |
79
|
||
EEA total number of subjects |
79
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
10
|
||
Adults (18-64 years) |
66
|
||
From 65 to 84 years |
3
|
||
85 years and over |
0
|
|
|||||||||||||||||||
Recruitment
|
|||||||||||||||||||
Recruitment details |
According to study protocol recruitment was planned to start in March 2015 and to be done within 18 months. Number of cases, statistical considerations, a total of 102 patients had to be included in this study (refer to study protocol chapter 9.1). The last follow-up included into this report took place on June 8th, 2018. | ||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||
Screening details |
As already mentioned hardly any data are documented concerning the pre-screening process and therefore the reasons, why patients could not be screened for the study. | ||||||||||||||||||
Period 1
|
|||||||||||||||||||
Period 1 title |
Overall trial (overall period)
|
||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||
Roles blinded |
Subject, Investigator | ||||||||||||||||||
Blinding implementation details |
The study was done double blinded (patients and treating physicians) but due to the known side effects of amitriptyline it must be feared that physicians as well as patients knew which
treatment they got.
|
||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
Amitriptyline arm | ||||||||||||||||||
Arm description |
Amitriptyline | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Amitriptyline
|
||||||||||||||||||
Investigational medicinal product code |
549-18-8
|
||||||||||||||||||
Other name |
Elavil
|
||||||||||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Amitriptyline 2 x 12.5 mg oral (day 1-14), followed by 2x25mg twice daily (day 15-98).
|
||||||||||||||||||
Arm title
|
Placebo arm | ||||||||||||||||||
Arm description |
- | ||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||
Investigational medicinal product name |
Placebo (corn starch)
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Placebo (corn starch) 2 x 12.5 mg oral (day 1-14), followed by 2x25mg twice daily (day 15-98)
|
||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall trial
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Amitriptyline arm
|
||
Reporting group description |
Amitriptyline | ||
Reporting group title |
Placebo arm
|
||
Reporting group description |
- |
|
|||||||||||||
End point title |
Difference between baseline and week 8 in FEV1% [1] | ||||||||||||
End point description |
Difference in absolute FEV1 % predicted between verum and placebo at week 8 compared to baseline
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
8 weeks
|
||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Statistical analyses can be found in the attached chart |
|||||||||||||
|
|||||||||||||
Attachments |
Primary endpoint statitical analysis |
||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Absolute and relative FEV1 as 2. Absolute and relativeFEV1 as % predicted after 4, 8 and 16 weeks compared tobaseline, if not primary | ||||||||||||
End point description |
Absolute and relative FEV1 as 2. Absolute and relative FEV1 as % predicted after 4, 8 and 16 weeks compared to baseline, if not primary
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
between week 8 and week 16
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
FEV1 [L] | ||||||||||||
End point description |
Absolute and relative FEV1 increase
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Until study termination (20 weeks)
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Other lung function parameters (FVC) (%) | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
16 weeks
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Other lung function parameters (FVC) (L) | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
16 weeks
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||
Adverse events information [1]
|
|||
Timeframe for reporting adverse events |
The trial duration and the follow up period
|
||
Assessment type |
Systematic | ||
Dictionary used for adverse event reporting
|
|||
Dictionary name |
MedDRA | ||
Dictionary version |
1
|
||
Frequency threshold for reporting non-serious adverse events: 0% | |||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: Information regarding Adverse Events can be found in the attached documents |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |